Combination therapy places no greater burden on early-stage breast cancer patients

[News]

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.

More... (https://www.news-medical.net/news/20201210/Combination-therapy-places-no-greater-burden-on-early-stage-breast-cancer-patients.aspx)